A Critical Inflection Point: The Indisputable Case for Next-Gen Pharmacovigilance - Qinecsa

A Critical Inflection Point: The Indisputable Case for Next-Gen Pharmacovigilance

Qinecsa COO, John Cogan, has been featured in Pharmaceutical Outsourcing’s latest issue, where he discusses why adverse event case processing is an enormous cost center and compliance issue for life sciences and outsourcing can alleviate pressure, free up internal resources, and drive down cost.

Read article

Recent Articles

The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?

Embracing quantitative signal detection methods as a smaller MAH

Real-Time Safety Signals Drive Continuous PV Insight

From Complaint Handling to Active Surveillance

Continuous Safety Surveillance for Medical Devices

Are patient outcomes getting lost in safety data complexity?

PreviousAI Encompassing: From Soaring Caseloads to Broadened Biopharma Territory

NextStaying Ahead of Regulatory Revisions